The Supreme Court is set to address how much information generic drug manufacturers can disclose about their products without infringing on existing patents, particularly in Hikma v. Amarin.
The complexity arises after initial patents expire for the original drug composition, as doctors and patients may favor generics for patented treatment regimens, raising 'inducing infringement' concerns.
Collection
[
|
...
]